Breathtaking Innovation
When lung infections are on the line, every minute counts.
The rapid Avisa BreathTest™, currently in late-stage clinical development, can detect lung bacterial infection in 10 minutes.
CSE: AVBT $0.36
Post COVID-19 "Long Haulers"
COVID-19 Pandemic Heightens Need for Rapid Pulmonary Diagnostic Innovation
50% of COVID-19 deaths are co-infected with bacterial pneumonia
Ventilator Associated Pneumonia (VAP)
30% to 50% mortality rate of patients with VAP
The world's first breath test designed to detect & monitor pulmonary infections.
The only test that has the potential to differentiate a virulent bacterial infection from strep pneumonia and viral lung infection.
A Value-Based, Cost Advantaged Product would be a Win for Patient, Doctor, Hospital and Payer
| AVISA BreathTest | Culture | PCR | Procalcitonin, Proteomics Panel | |
|---|---|---|---|---|
| Specimen | Exhaled Breath | Sputum | Sputum | Blood |
| Detects live organisms | Yes | No | No | No |
| Measures whole lung | Yes | No | No | No |
| Monitors treatment | Yes | No | No | Yes |
| Turnaround time | <10 min | 24 hrs to 3 days | 4 hrs to 24 hrs | 2 hrs to 4 hrs |
| Sensitivity | High | Low | Moderate | Moderate |
| Specificity | High Urease | High | High | Low |
| Point of care, portable | Yes | No | No | No |
| Test complexity | Low | High | High | Moderate |
| Complementary to ABT | --- | Yes | Yes | No |